Tag: Non-Hodgkin Lymphoma
Epcoritamab shows promising response rates seen in relapsed or refractory non-Hodgkin lymphoma
1. Full-dose regimens of 48-60 mg achieved clinically significant response rates varying from 68-100%. 2. No dose-limiting toxic effects were ...
#VisualAbstract: Topical calcineurin inhibitor use is associated with an increased risk of lymphoma
Click to read the study in JAMA Dermatology.
Pirtobrutinib is safe and efficacious in the treatment of relapsed or refractory B-cell malignancies (BRUIN Trial)
1. Bruton’s tyrosine kinase inhibitor pirtobrutinib showed efficacy in the treatment of relapsed or refractory B-cell malignancies such as chronic ...
Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes
1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or ...
Rituximab after autologous stem cell transplantation in mantle cell lymphoma patients prolongs survival
1. Patients with mantle cell lymphoma treated with autologous stem cell transplantation experienced greater overall, event-free, and progression-free survival when ...
HBV and HCV coinfection may increase non-Hodgkin’s lymphoma risk in HIV-infected patients
1. Compared to the HIV-negative population, chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection was found to ...
Patient Basics: Non-Hodgkin Lymphoma
Originally published by Harvard Health. What Is It? Non-Hodgkin lymphoma is a group of about 30 different blood cancers. It is ...
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
